A new publication by Professor Bryan Spring and his team at Northeastern University has shown promising results for improved photoimmunotherapy protocols using patient-derived ovarian cancer cells. Using Modulight’s ML6000-series laser as part of the new protocol, they successfully minimized non-specific damage to cells that was caused by a small fraction of non-covalently bound (free) photosensitive drug, which is typically cleared in vivo by lymph and blood flow. They also showed the importance of using more biologically relevant cancer cell models for drug testing, since they better reflected tumors compared to typically used immortalized cell lines. We think this work is important as it will help researchers in expanding the use of photoimmunotherapy, which is currently clinically used for head and neck cancers.

Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!

Modulight products used:

ML6600 – High-power laser system with multi-wavelength support

Read more:

In-vitro and in-vivo illumination »

About Modulight’s LASER-SHARP RESEARCH concept:

Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.